Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass., July 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on July 1, 2024 the Company granted inducement awards to purchase up to 124,000 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
美国马萨诸塞州沃尔瑟姆，2024年7月5日/美通社/--Syndax Pharmaceuticals（纳斯达克: SNDX） ，一家临床阶段的生物制药公司，正在开发一系列创新的癌症治疗方案。今天宣布，在2023年引诱计划下，公司于2024年7月1日向8名新员工授予期权，以购买高达124,000股普通股。股票期权将于四年内归属，其中基础股份的25%将在归属开放日期的一周年纪念日上归属，并在此后36个月内每月归属1/48的基础股份，前提是员工与Syndax继续保持服务关系，直至适用的归属日期。
About Syndax
关于Syndax
Syndax is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective menin inhibitor, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit or follow the Company on X (formerly Twitter) and LinkedIn.
Syndax是一家临床阶段的生物制药公司，正在开发一系列创新的抗癌治疗药物。该公司的产品管线包括高度选择性Menin抑制剂revumenib和单克隆抗体axatilimab，该抗体可阻断集落刺激因子1（CSF-1）受体。欲了解更多信息，请访问 noted website 或在X（前身为Twitter）和LinkedIn上关注该公司。
Syndax Contact
Syndax联系人
Sharon Klahre
Syndax Pharmaceuticals, Inc.
[email protected]
Tel 781.684.9827
Sharon Klahre
Syndax Pharmaceuticals，Inc.
[email protected]
电话 781.684.9827
SOURCE Syndax Pharmaceuticals, Inc.
消息来源：Syndax Pharmaceuticals，Inc。